Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies.
The wide-ranging, multisystemic manifestations of sarcoidosis can make diagnosis and management difficult. Corticosteroid treatment is effective, but the optimal time to start, the dose, and the duration of treatment are controversial. We are just beginning to understand the genetic basis of sarcoidosis.
Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Daniel A
DA
Culver
Mary Jane
MJ
Thomassen
Mani S
MS
Kavuru
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001706:Biopsy; D017322:Clinical Trials, Phase II as Topic; D004198:Disease Susceptibility / Q000209:etiology; D015769:Granuloma, Respiratory Tract / Q000453:epidemiology / Q000473:pathology; D006331:Heart Diseases / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D000069285:Infliximab; D008171:Lung Diseases / Q000175:diagnosis / Q000453:epidemiology; D010166:Palliative Care; D015995:Prevalence; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000517:prevention & control; D044469:Racial Groups; D017565:Sarcoidosis, Pulmonary / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab